Global Diabetes Market Trends & Future Forecast

Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

Product Code RNR00011
Publication Date June 2010
Publisher Renub Research
Product Type Report
Pages 114
ISBN Number not applicable
Change currency
PDF £695.00 €837 $1,099 BUY >
PRINT £790 €951 $1,249 BUY >
CDROM £790 €951 $1,249 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Global Diabetes Market Trends & Future Forecast

Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

Report Details

"Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1" report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering:

  • Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
  • Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
  • Region wise Diabetes Health Expenditure and Mortality
  • Top 10 Countries Diabetes Population and Future Forecast
  • Top 5 Countries Diabetes Drug Market and Future Forecast
  • Top 7 Countries Insulin Market and Future Forecast
  • Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market
  • Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market
  • Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
  • Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market

Research Highlights

  • USA controls more than 50% of the total Diabetes Drug market share in 2009
  • Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
  • China will have the second highest Insulin market share by 2012 replacing Germany
  • DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
  • GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
  • Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
  • Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
  • Januvia is proving a blockbuster of DPP - IV Inhibitors segment expected to be more than US$ 4 Billion by 2017
  • Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists
  • China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
  • Japan Insulin market is expected to be more than US$ 1 Billion by 2010

Key Drugs Analyzed

Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix
Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus
DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus,
GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.

Contents

  • 1. Executive Summary
  • 2. Global Diabetes Market
    • 2.1 Global - Diabetes Drug Market & Future Forecast
    • 2.2 Global - Insulin Market & Future Forecast
    • 2.3 Global - Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India)
    • 2.4 Global - Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan, USA, India)
    • 2.5 Global - Dipeptidyl Peptidase (DPP - IV) Inhibitors Market & Future Forecast
    • 2.6 Global - Glucagon-like Peptide-1(GLP-1) Market & Future Forecast
  • 3. Global - Top 6 Diabetes Drug Brands Market Performance
    • 3.1 Avandia - Past & Present Market
    • 3.2 Actos - Past, Present & Future Forecast
    • 3.3 Amaryl - Past, Present & Future Forecast
    • 3.4 Avandamet - Past, Present & Future Forecast
    • 3.5 Prandin/Novonorm - Past & Present Market
    • 3.6 Starlix - Past, Present & Future Forecast
  • 4. Global - Top 9 Insulin Brands Market Performance
    • 4.1 Novomix - Past, Present & Future Forecast
    • 4.2 Novorapid - Past, Present & Future Forecast
    • 4.3 Levemir - Past, Present & Future Forecast
    • 4.4 Degludec - Yet to be Launched - Future Forecast
    • 4.5 Degludecplus - Yet to be Launched - Future Forecast
    • 4.6 Humalog - Past & Present Market
    • 4.7 Humulin - Past & Present Market
    • 4.8 Apidra - Past, Present & Future Forecast
    • 4.9 Lantus - Past, Present & Future Forecast
  • 5. Global - DPP-IV Inhibitors Brands Market Performance
    • 5.1 Januvia - Past, Present & Future Forecast
    • 5.2 Onglyza - Past, Present & Future Forecast
    • 5.3 Alogliptin - Yet to be Launched - Future Forecast
    • 5.4 Galvus - Past, Present & Future Forecast
    • 5.5 DPP-IV Inhibitors - In Trial Phases
  • 6. Global - GLP-1 Agonists Brands Market Performance
    • 6.1 Byetta - Past, Present & Future Forecast
    • 6.2 Victoza - Past, Present & Future Forecast
    • 6.3 Exenatide LAR - Yet to be Launched - Future Forecast
    • 6.4 Syncria - Yet to be Launched - Future Forecast
    • 6.5 Taspoglutide - Yet to be Launched - Future Forecast
  • 7. Regional Estimates for Diabetes
    • 7.1 Diabetes - Population & Prevalence
    • 7.2 Impaired Glucose Tolerance (IGT) - Population & Prevalence
    • 7.3 Mortality - Due to Diabetes
    • 7.4 North America & Caribbean Region
      • 7.4.1 Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
      • 7.4.2 Healthcare Expenditure & Type 1 Diabetes
      • 7.4.3 Mortality
    • 7.5 Middle East and North African Region
      • 7.5.1 Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
      • 7.5.2 Healthcare Expenditure & Type 1 Diabetes
      • 7.5.3 Mortality
    • 7.6 South-East Asian Region
      • 7.6.1 Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
      • 7.6.2 Healthcare Expenditure & Type 1 Diabetes
      • 7.6.3 Mortality
    • 7.7 European Region
      • 7.7.1 Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
      • 7.7.2 Healthcare Expenditures & Type 1 Diabetes
      • 7.7.3 Mortality
    • 7.8 South and Central American Region
      • 7.8.1 Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
      • 7.8.2 Healthcare Expenditures & Type 1 Diabetes
      • 7.8.3 Mortality
    • 7.9 Western Pacific Region
      • 7.9.1 Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
      • 7.9.2 Healthcare Expenditures & Type 1 Diabetes
      • 7.9.3 Mortality
    • 7.10 African Region
      • 7.10.1 Diabetes & Impaired Glucose Tolerance (IGT) - Population & Prevalence
      • 7.10.2 Healthcare Expenditure & Type 1 Diabetes
      • 7.10.3 Mortality
  • 8. Global - Top 10 Diabetic Countries Performance
    • 8.1 Number of People in Top 10 Diabetic Place
    • 8.2 Prevalence of Diabetes in Top 10 Countries
    • 8.3 India
      • 8.3.1 Diabetes Population & Future Scenario
      • 8.3.2 India - Diabetes Drug Market & Future Forecast
      • 8.3.3 India-Insulin Market & Future Forecast
    • 8.4 China
      • 8.4.1 Diabetes Population & Future Scenario
      • 8.4.2 Diabetes Drug Market & Future Forecast
      • 8.4.3 China Insulin Market & Future Forecast
    • 8.5 United States
      • 8.5.1 Diabetes Population & Future Scenario
      • 8.5.2 Diabetes Drug Market & Future Forecast
      • 8.5.3 Insulin Market & Future Forecast
    • 8.6 Brazil
      • 8.6.1 Diabetes Population & Future Scenario
      • 8.6.2 Diabetes Drug Market & Future Forecast
    • 8.7 Russia
      • 8.7.1 Diabetes Population & Future Scenario
      • 8.7.2 Insulin Market & Future Forecast
    • 8.8 Japan
      • 8.8.1 Diabetes Population & Future Scenario
      • 8.8.2 Diabetes Drug Market & Future Forecast
      • 8.8.3 Insulin Market & Future Forecast
    • 8.9 Germany
      • 8.9.1 Diabetes Population & Future Scenario
      • 8.9.2 Insulin Market & Future Forecast
    • 8.10 Mexico
      • 8.10.1 Diabetes Population & Future Scenario
      • 8.10.2 Insulin Market & Future Forecast
    • 8.11 Indonesia
      • 8.11.1 Diabetes Population & Future Scenario
    • 8.12 Pakistan
      • 8.12.1 Diabetes Population & Future Scenario
  • List of Figures:
    • Figure 2 1: Global - Diabetes Drug Market (Billion US$), 2005 - 2009
    • Figure 2 2: Global - Forecast of Diabetes Drug Market (Billion US$), 2010 - 2013
    • Figure 2 3: Global - Insulin Market (Billion US$), 2004 - 2009
    • Figure 2 4: Global - Forecast of Insulin Market (Billion US$), 2010 - 2013
    • Figure 2 5: Global - Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2007 - 2009
    • Figure 2 6: Global - Forecast of Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2010 - 2013
    • Figure 2 7: Global - Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India) (Percent), 2007 - 2009
    • Figure 2 8: Global - Forecast for Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India) (Percent), 2010 - 2013
    • Figure 2 9: Global - DPP - IV Inhibitors Market (Million US$), 2009 - 2015
    • Figure 2 10: Global - GLP-1 Market (Million US$), 2009 - 2015
    • Figure 3 1: Global - Avandia Diabetes Drug Brand Sales (Million US$), 2004 - 2009
    • Figure 3 2: Global - Actos Diabetes Drug Sales (Billion US$), 2005 - 2009
    • Figure 3 3: Global - Forecast for Actos Diabetes Drug Sales (Billion US$), 2010 & 2013
    • Figure 3 4: Global - Amaryl Diabetes Drug Sales (Million US$), 2006, 2007, 2009, & Q1 2010
    • Figure 3 5: Global - Forecast for Amaryl Diabetes Drug Sales (Million US$), 2010 - 2012
    • Figure 3 6: Global - Avandamet Diabetes Drug Sales (Million US$), 2006 - 2009
    • Figure 3 7: Global - Forecast for Avandamet Diabetes Drug Sales (Million US$), 2010 - 2012
    • Figure 3 8: Global - Prandin/Novonorm Diabetes Drug Sales (Million US$), 2007 - 2009
    • Figure 3 9: Global - Starlix Diabetes Drug Sales (Million US$), 2007 - 2009E
    • Figure 3 10: Global - Forecast for Starlix Diabetes Drug Sales (Million US$), 2010 - 2012
    • Figure 4 1: Global - NovoMix Insulin Sales (Million US$), 2005 - 2009
    • Figure 4 2: Global - NovoRapid Insulin Sales (Million US$), 2005 - 2009
    • Figure 4 3: Global - Levemir Insulin Sales (Million US$), 2005 - 2009
    • Figure 4 4: Global - Humalog Insulin Sales (Million US$), 2006 - 2009
    • Figure 4 5: Global - Humulin Insulin Brand Sales (Million US$), 2006 - 2009
    • Figure 4 6: Global - Apidra Insulin Sales (Million US$), 2005 - 2009, Q1 2010
    • Figure 4 7: Apidra - Forecast for Insulin Sales (Million US$), 2009 - 2013
    • Figure 4 8: Global - Lantus Insulin Sales (Million US$), 2006 - 2009, Q1 2010
    • Figure 4 9: Global - Forecast for Lantus Insulin Sales (Million US$), 2010 - 2015
    • Figure 5 1: Global - Januvia DPP-IV Inhibitors Sales (Million US$), 2007 - 2009
    • Figure 5 2: Global - Forecast for Januvia DPP-IV Inhibitors Sales (Million US$), 2010 - 2017
    • Figure 5 3: Global - Onglyza DPP-IV Inhibitors Sales & Future Forecast (Million US$), 2009 - 2017
    • Figure 5 4: Global - Future Forecast for Alogliptin DPP-IV Inhibitors Sale (Million US$), 2011 - 2017
    • Figure 5 5: Global - Galvus DPP-IV Inhibitors Sale (Million US$), 2007 - 2009
    • Figure 5 6: Global - Future Forecast for Galvus DPP-IV Inhibitors Sale (Million US$), 2010 - 2012
    • Figure 6 1: Global - Byetta GLP-1 Sales (Million US$), 2006 - 2009
    • Figure 6 2: Global - Forecast for Byetta GLP-1 Sales (Million US$), 2010 - 2017
    • Figure 6 3: Global - Victoza GLP-1 Sales & Future Forecast (Million US$), 2009 - 2017
    • Figure 6 4: Global - Forecast for Exenatide LAR GLP-1 Sales (Million US$), 2011 - 2017
    • Figure 6 5: Global - Forecast for Syncria GLP-1 Sales (Million US$), 2013 - 2017
    • Figure 6 6: Global - Forecast for Taspoglutide GLP-1 Sales (Million US$), 2012 - 2017
    • Figure 8 1: India - Number of People with Diabetes (Million), 2003, 2007, 2010
    • Figure 8 2: India - Diabetes Drug Market (Billion INR), 2006 - 2009
    • Figure 8 3: India - Forecast for Diabetes Drug Market (Billion INR), 2010 - 2014
    • Figure 8 4: India - Share of Human Insulin Market, Animal Insulin Market & Oral Diabetes Market (in Percent), 2003 & 2007
    • Figure 8 5: India - Insulin Market (Million INR), 2006 - 2009
    • Figure 8 6: India - Forecast for Insulin Market (Million INR), 2010 - 2014
    • Figure 8 7: China - Number of Diabetes Patients (Million), 2003, 2007 & 2010
    • Figure 8 8: China - Diabetes Drug Market (Billion Yuan), 2006 - 2009E
    • Figure 8 9: China - Forecast for Diabetes Drug Market (Billion Yuan) 2010 - 2014
    • Figure 8 10: China - Insulin Market (Million Yuan), 2007 - 2009
    • Figure 8 11: China - Forecast for Insulin Market (Million Yuan), 2010 - 2014
    • Figure 8 12: USA - Number of Diabetes Patients (Million), 2003, 2006, 2007 & 2010
    • Figure 8 13: USA - Diabetes Drug Market (Million US$), 2002 - 2009
    • Figure 8 14: USA - Forecast for Diabetes Drug Market (Million US$), 2010 - 2014
    • Figure 8 15: USA - Insulin Market (Billion US$), 2003 - 2009
    • Figure 8 16: USA - Forecast for Insulin Market (Billion US$), 2010 - 2014
    • Figure 8 17: Brazil - Diabetes Population (Million), 2003, 2007 & 2010
    • Figure 8 18: Brazil - Diabetes Drug Market (Million US$), 2008 - 2013
    • Figure 8 19: Russia - Number of Diabetes Population (Million), 2005 & 2010
    • Figure 8 20: Russia - Insulin Market (Million US$), 2002, 2005 - 2009
    • Figure 8 21: Russia - Forecast for Insulin Market (Million US$), 2010 - 2014
    • Figure 8 22: Japan - Number of Diabetes Population (Million), 2003 - 2010
    • Figure 8 23: Japan - Diabetes Drug Market (Million US$), 2002 - 2009
    • Figure 8 24: Japan - Forecast for Diabetes Market (Million US$), 2010 - 2014
    • Figure 8 25: Japan - Insulin Market (Million US$), 1998 - 2009
    • Figure 8 26: Japan - Forecast for Insulin Market (Million US$), 2010 - 2014
    • Figure 8 27: Germany - Number of Diabetes Patients (Million), 2003 - 2010
    • Figure 8 28: Germany - Insulin Market (Million US$), 2004 - 2009E
    • Figure 8 29: Germany - Forecast for Insulin Market (Billion US$), 2010 - 2014
    • Figure 8 30: Mexico - Number of People with Diabetes (Million), 2003 - 2005, 2007 & 2010
    • Figure 8 31: Mexico - Insulin Market (Million US$), 2004 - 2009E
    • Figure 8 32: Mexico - Forecast for Insulin Market (Million US$), 2010 - 2014
    • Figure 8 33: Pakistan - Number of Diabetes Patients (Million), 2003, 2007 & 2010
  • List of Tables:
    • Table 4 1: Novomix - Forecast for Insulin Sales (Million US$), 2010 - 2030
    • Table 4 2: Global - Forecast for NovoRapid Insulin Sales (Million US$), 2010 - 2030
    • Table 4 3: Global - Forecast for Levemir Insulin Sales (Million US$), 2010 - 2030
    • Table 4 4: Degludec - Forecast for Insulin Sales (Million US$), 2010 - 2030
    • Table 4 5: DegludecPlus - Forecast for Insulin Sales (Million US$), 2010 - 2030
    • Table 5 1: DPP-4 Inhibitors -In Trial Phase
    • Table 7 1: Regional - Estimates for (Number of People with Diabetes, Comparative Diabetes Prevalence %) (20-79 years), 2010 and 2030
    • Table 7 2: Regional - Estimates for (Number of People with IGT, Comparative IGT Prevalence %) (20-79 years), 2010 and 2030
    • Table 7 3: Regional - Diabetes Mortality (20-79 Years; Thousand), 2010
    • Table 7 4: North America and Caribbean Region - Population & Adult Population (Million), 2010 & 2030
    • Table 7 5: North America and Caribbean Region - Number of People with Diabetes & Comparative Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030
    • Table 7 6: North America and Caribbean Region - Number of People with IGT & Comparative Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030
    • Table 7 7: North America and Caribbean Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    • Table 7 8: North America and Caribbean Region - Diabetes Mortality (20-79 Years; Thousand), 2010
    • Table 7 9: Middle East and North African Region - Population & Adult Population (Million), 2010 & 2030
    • Table 7 10: Middle East and North African Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    • Table 7 11: Middle East and North African Region - Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    • Table 7 12: Middle East and North African Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    • Table 7 13: Middle East and North African Region - Diabetes Mortality (20-79 Years; Thousand), 2010
    • Table 7 14: South-East Asian Region - Population & Adult Population (Million), 2010 & 2030
    • Table 7 15: South-East Asian Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    • Table 7 16: South-East Asian Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    • Table 7 17: South-East Asian Region - Diabetes Mortality (20-79 Years; Thousand), 2010
    • Table 7 18: European Region - Population & Adult Population (Million), 2010 & 2030
    • Table 7 19: European Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million Percent), 2010 & 2030
    • Table 7 20: European Region - Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    • Table 7 21: European Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    • Table 7 22: European Region - Diabetes Mortality (20-79 Years; Thousand), 2010
    • Table 7 23: South and Central American Region - Population & Adult Population (Million), 2010 & 2030
    • Table 7 24: South and Central American Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    • Table 7 25: South and Central American Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    • Table 7 26: South and Central American Region - Diabetes Mortality (20-79 Years; Thousand), 2010
    • Table 7 27: Western Pacific Region - Population & Adult Population (Million), 2010 & 2030
    • Table 7 28: Western Pacific Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    • Table 7 29: Western Pacific Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    • Table 7 30: Western Pacific Region - Diabetes Mortality (20-79 Years; Thousand), 2010
    • Table 7 31: African Region - Population & Adult Population (Million), 2010 & 2030
    • Table 7 32: African Region - Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    • Table 7 33: African Region - Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    • Table 7 34: African Region - Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    • Table 7 35: African Region - Diabetes Mortality (20-79 Years; Thousand), 2010
    • Table 8 1: Global - Top 10 Countries Number of People with Diabetes (20-79 age group) (Million) 2010 & 2030
    • Table 8 2: Global - Top 10 Countries in Prevalence of Diabetes (20-79 age group) (Percent), 2010 & 2030
    • Table 8 3: India - Forecast for Number of People with Diabetes (Million), 2011 - 2030
    • Table 8 4: China - Forecast for Number of Diabetes Patients (Million), 2011 - 2030
    • Table 8 5: USA - Forecast for Number of Diabetes Patients (Million), 2011 - 2030
    • Table 8 6: Brazil - Forecast for Number of Diabetes Population (Million), 2011 - 2030
    • Table 8 7: Russia - Forecast for Number of Diabetes Population (Million), 2011 - 2030
    • Table 8 8: Mexico - Forecast for Number of Diabetes Patients (Million), 2011 - 2030
    • Table 8 9: Indonesia - Forecast for Number of Diabetes Patients (Million), 2010 - 2030
    • Table 8 10: Pakistan - Forecast for Number of Diabetes Patients (Million), 2011 - 2030